ImageneBio, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ImageneBio, Inc. (IMA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $18.90 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-07-24.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-07-24
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.63M.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$67.04M.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$30.59M.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$185.34M, a 256.38% decline year-over-year.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$80.91M, a 233.99% decline from fiscal 2023.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $60.38M.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$172.30M, a 347.11% decline from fiscal 2021.
- ImageneBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $69.73M, a 14.22% decline from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-06-30 | $18.90M 10-Q · filed 2025-07-24 | |||
| 2025-03-31 | -$2.63M 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | -$80.91M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$75.11M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$75.63M 10-Q · filed 2025-07-24 | |||
| 2024-03-31 | -$67.04M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $60.38M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $61.76M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $10.95M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$30.59M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$172.30M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | -$165.14M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$183.73M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$185.34M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $69.73M 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $83.41M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $101.51M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $118.52M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $81.28M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | -$25.35M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$17.68M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$9.97M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |